Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Reaches Agreement with FDA under Special Protocol Assessment for Pivotal Trial Evaluating RE-024 in PKAN
Phase 3 trial expected to initiate before year-end 2016
View HTML
Toggle Summary Retrophin Reports Third Quarter 2016 Financial Results
Positive top-line results from DUET announced in September; additional data to be presented at ASN Kidney Week 2016 Third quarter revenues increased 21 percent year-over-year SAN DIEGO , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today reported its third quarter 2016 financial
View HTML
Toggle Summary Retrophin to Present Additional Data from Phase 2 DUET Study of Sparsentan in Late-Breaking Oral Session at ASN Kidney Week 2016
SAN DIEGO , Oct. 21, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that additional data from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS) will be presented at the late-breaking High-Impact Clinical Trials oral session
View HTML
Toggle Summary Retrophin to Report Third Quarter 2016 Financial Results
SAN DIEGO , Oct. 20, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report third quarter 2016 financial results on Thursday, November 3, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Dr. Alvin Shih Departing Retrophin to Lead Biotechnology Start-Up
SAN DIEGO , Oct. 06, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced Alvin Shih , M.D., will be stepping down from his position as executive vice president and head of research and development to become chief executive officer of a start-up biotechnology company. Dr.
View HTML
Toggle Summary Retrophin Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO , Sept. 30, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that its Board of Directors has granted an inducement award pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules to Julio Gagne in connection with his employment as vice president, Program Management.
View HTML
Toggle Summary Retrophin to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series
SAN DIEGO , Sept. 14, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Alvin Shih , M.D., executive vice president and head of research & development, will present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series in New York City on Wednesday,
View HTML
Toggle Summary Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis
     Combined sparsentan treatment group experienced 44.8 percent reduction of proteinuria, more than double the reduction of irbesartan; achieves statistical significance in primary efficacy endpoint Preliminary safety findings show sparsentan was generally safe and well-tolerated Conference call
View HTML
Toggle Summary Retrophin Appoints Neil McFarlane Chief Operating Officer
SAN DIEGO , Aug. 15, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced Neil McFarlane has been appointed chief operating officer. In this newly created position, Mr. McFarlane will help guide the Company's daily operations with principal responsibility for commercial
View HTML
Toggle Summary Retrophin Reports Second Quarter 2016 Financial Results
Second quarter revenues increased 38 percent year-over-year Sparsentan top-line data expected in third quarter of 2016 RE-024 efficacy trial expected to initiate in second half of 2016 SAN DIEGO , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today reported its second quarter 2016
View HTML